NNOX Nano-X Imaging Earnings Miss: EPS Down 117% vs Estimate

NNOX reported disappointing first-quarter earnings on April 20, 2026, missing both EPS and revenue expectations. The medical imaging company posted a loss per share of negative $0.50, significantly worse than the estimated negative $0.23. Revenue came in at $3.72 million, falling short of the $4.25 million forecast by 12.5%. This marks the weakest earnings performance in Nano-X’s recent quarterly history. The stock showed resilience, gaining 0.7% to $2.17 despite the miss. Meyka AI rates NNOX with a grade of B, reflecting mixed fundamentals in a challenging period for the company.

NNOX Earnings Miss: The Numbers

Nano-X Imaging delivered a significant earnings disappointment in Q1 2026. The company’s loss per share deteriorated sharply from expectations.

EPS Performance Deteriorates

NNOX reported EPS of negative $0.50, representing a 117% miss versus the negative $0.23 estimate. This marks the worst quarterly loss per share in the past four quarters. The prior quarter showed negative $0.15 EPS, while two quarters back the loss was negative $0.23. The widening losses suggest operational challenges intensified during the quarter.

Revenue Falls Below Forecast

Revenue totaled $3.72 million, down 12.5% from the $4.25 million estimate. This represents the lowest quarterly revenue in recent periods. The previous quarter generated $4.1 million in revenue, showing a sequential decline of 9.3%. Two quarters prior, revenue was $3.04 million, indicating volatility in the company’s top-line performance.

Market Cap and Stock Response

Despite the earnings miss, NNOX stock gained 0.7% to close at $2.17. The company maintains a market capitalization of $151.4 million. The stock has declined significantly year-to-date, down 22.3%, and is off 54.2% over the past 12 months, reflecting broader investor concerns about the company’s path to profitability.

Quarterly Trends: Deteriorating Performance

Examining the past four quarters reveals a troubling pattern for Nano-X Imaging. The company continues burning cash while struggling to grow revenue consistently.

EPS Trend Worsens

The EPS trajectory shows deterioration. Q1 2026 loss of negative $0.50 is the worst result in the recent period. The prior quarter’s negative $0.15 was better, while two quarters back showed negative $0.23. This quarter’s loss is 2.2 times worse than the previous quarter, signaling accelerating operational challenges.

Revenue Volatility Persists

Revenue performance lacks consistency. Q1 2026 at $3.72 million is below the prior quarter’s $4.1 million. Two quarters back showed $3.04 million, while three quarters prior was $2.82 million. The company has not achieved sustained revenue growth, with Q1 representing a step backward from recent quarters.

Cumulative Losses Mount

Over the past four quarters, NNOX has accumulated significant losses. The company remains unprofitable with negative net margins of 5.8%. Operating cash flow is negative, and free cash flow remains deeply negative. This pattern suggests the company is consuming cash reserves while searching for a path to profitability.

Financial Health and Operational Metrics

Nano-X’s balance sheet shows some strength, but operational metrics reveal serious challenges. The company maintains adequate liquidity but faces profitability headwinds.

Liquidity Position Remains Strong

NNOX maintains a current ratio of 3.96, indicating strong short-term liquidity. Cash per share stands at $0.73, providing a cushion for operations. The company has minimal debt with a debt-to-equity ratio of just 2.9%. Working capital totals $49.9 million, offering runway for continued operations despite ongoing losses.

Profitability Metrics Deteriorate

Gross profit margin is deeply negative at negative 80.2%, indicating the company loses money on every dollar of revenue. Operating margin stands at negative 455.5%, while net profit margin is negative 576.1%. Return on equity is negative 47.1%, and return on assets is negative 46.3%. These metrics show the company is far from sustainable operations.

Cash Burn Accelerates

Operating cash flow per share is negative $0.63, while free cash flow per share is negative $0.70. The company burns approximately $0.70 per share quarterly. At the current burn rate and cash position, the company has limited runway before requiring additional capital or achieving profitability.

What’s Next for NNOX

Nano-X faces critical challenges ahead. The company must demonstrate a clear path to profitability or risk significant shareholder dilution through capital raises.

Path to Profitability Unclear

The company’s medical imaging technology remains in development stages. Revenue growth has stalled, and losses are accelerating. Management must articulate a credible strategy to reach profitability. Without significant operational improvements or revenue acceleration, the company’s cash runway becomes increasingly constrained.

Analyst Sentiment Mixed

Two analysts rate NNOX as a buy, while none rate it as hold or sell. However, the company rating from Meyka AI is C with a sell recommendation. The consensus reflects uncertainty about the company’s near-term prospects. The stock trades at a price-to-sales ratio of 11.6x, expensive for an unprofitable company.

Next Earnings Date

NNOX will report next earnings on May 27, 2026. Investors will watch for signs of revenue stabilization, reduced losses, or positive guidance. Any indication of accelerating cash burn or further revenue declines could pressure the stock lower.

Final Thoughts

Nano-X Imaging missed Q1 2026 earnings badly, with negative $0.50 EPS and $3.72 million revenue falling short of expectations. The company faces accelerating losses, negative gross margins, and concerning cash burn despite strong liquidity. With a C rating and sell recommendation, investors should demand proof of a path to profitability at the May earnings report.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.